[Chronic allograft dysfunction: role of immunosuppressive treatment]. / Disfunzione cronica del trapianto renale (CAD): ruolo della terapia immunosoppressiva.
G Ital Nefrol
; 25 Suppl 44: S48-S52, 2008.
Article
em It
| MEDLINE
| ID: mdl-19048586
ABSTRACT
Renal transplantation is the treatment of choice for patients with end-stage renal disease. In recent years a major improvement has been observed in short-term graft survival, but there has been no corresponding improvement in long-term survival. Chronic allograft dysfunction (CAD) is an anatomical and clinical alteration that can lead to the loss of the transplanted organ without any specific cause. The pathogenesis of CAD, which still remains to be fully clarified, involves both immunological factors (acute rejection, subclincial rejection, HLA mismatches between donor and recipient, noncompliance, etc) and non-immunological factors (marginal donor ischemia/reperfusion injury, infection, cardiovascular risk factors, nephrotoxicity, etc). Immunosuppressive therapy represents one of the strategies for the prevention of CAD. The introduction into clinical practice of novel immunosuppressive agents with no or lower nephrotoxicity, like mycophenolate mofetile, rapamycin and everolimus, will make therapeutic strategies aimed at decreasing the incidence of CAD feasible.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Transplante de Rim
/
Sirolimo
/
Rejeição de Enxerto
/
Imunossupressores
/
Nefropatias
/
Ácido Micofenólico
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
It
Ano de publicação:
2008
Tipo de documento:
Article